Clinical trial to test potential new therapy for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis (GCA). The study is sponsored by Kiniksa Pharmaceuticals, Ltd. Hospital for Special Surgery (HSS), in New York City, is one of the centers participating in the research.